Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Series A Non-Voting Convertible Preferred Stock	Series A Non-Voting Convertible Preferred Stock Preferred Stock	Series B Non-Voting Convertible Preferred Stock	Series B Non-Voting Convertible Preferred Stock Preferred Stock
Beginning balance, preferred stock (in shares) at Dec. 31, 2024							346,000		17,000
Beginning balance at Dec. 31, 2024	$ 517,804	$ 13	$ 1,334,223	$ 180	$ (972,432)		$ 146,425		$ 9,395
Beginning balance, common stock (in shares) at Dec. 31, 2024		60,257,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)		19,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	218		218
Stock-based compensation expense	8,859		8,859
Foreign currency translation adjustment	14			14
Unrealized gain on marketable securities	488			488
Net loss	(44,773)				(44,773)	$ (8,288)		$ (399)
Ending balance, preferred stock (in shares) at Mar. 31, 2025							346,000		17,000
Ending balance at Mar. 31, 2025	482,610	$ 13	1,343,300	682	(1,017,205)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Mar. 31, 2025		60,276,000
Beginning balance, preferred stock (in shares) at Dec. 31, 2025						346,045	346,000	16,667	17,000
Beginning balance at Dec. 31, 2025	$ 715,236	$ 15	1,686,167	869	(1,127,635)		$ 146,425		$ 9,395
Beginning balance, common stock (in shares) at Dec. 31, 2025	78,189,811	78,190,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with at-the-market offering program, net of financing costs (in shares)		296,000
Issuance of common stock in connection with at-the-market offering program, net of financing costs	$ 9,747		9,747
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)		354,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	3,663		3,663
Stock-based compensation expense	12,806		12,806
Foreign currency translation adjustment	0
Unrealized gain on marketable securities	(1,636)			(1,636)
Net loss	(69,005)				(69,005)	$ (10,264)		$ (494)
Ending balance, preferred stock (in shares) at Mar. 31, 2026						346,045	346,000	16,667	17,000
Ending balance at Mar. 31, 2026	$ 670,811	$ 15	$ 1,712,383	$ (767)	$ (1,196,640)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Mar. 31, 2026	78,839,858	78,840,000